pyrazines has been researched along with Animal Mammary Carcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brooks, AD; Elliott, PJ; Murphy, WJ; Sayers, TJ; Shanker, A; Smyth, MJ; Takeda, K; Tristan, CA; Wine, JW; Yagita, H | 1 |
1 other study(ies) available for pyrazines and Animal Mammary Carcinoma
| Article | Year |
|---|---|
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Humans; Immunoblotting; Kidney Neoplasms; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mitochondrial Membranes; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2008 |